Abstract
Purpose
Patients with hematological malignancies (HMs) are at a higher risk for bloodstream infections (BSIs), which pose significant burden on morbidity and mortality. Better risk stratification helps in medical decision making, increasing efficiency and reducing economic burden. The aim of this study was to develop and validate a reliable prediction model which can be used to identify HM patients at higher risk for BSIs.
Methods
We conducted a retrospective cohort study in three university-affiliated hospitals in Hunan Province, China, from January 2010 to April 2015. A total of 521 HMs patients with BSIs were finally included in this study and were divided into the derivation set and validation set. Survivors and non-survivors were compared to identify the predictors of 30-day mortality.
Results
The multivariate analysis yielded the following significant mortality-related risk factors: age > 60 years (95% CI 1.047–5.474), relapsed or uncontrolled malignancy (95% CI 2.043–14.029), Pitt bacteremia score > 3 (95% CI 1.614–6.35), prolonged neutropenia (95% CI 1.181–5.824), use of vasopressors (95% CI 3.009–12.210), acute respiratory failure (95% CI 3.061–14.911), fungemia (95% CI 1.334–12.121), inadequate antibiotic treatment (95% CI 1.682–7.591), albumin < 30 g/L (95% CI 1.030–3.446), TBil > 34.2 µmol/L (95% CI 1.109–5.438). In both derivation and validation sets, our model showed reliable prediction value with areas under the receiver operating curve of 0.876 and 0.873.
Conclusions
The risk factors in this study have the ability to identify patients with HMs and BSIs at high risk for mortality. Our model provides an excellent foundation for predicting 30-day morality in HM patients suffering from BSI and helps target high-risk patients for management decision making.
Similar content being viewed by others
References
Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect. 2006;12:217–23.
Tumbarello M, Spanu T, Caira M, Trecarichi EM, Laurenti L, Montuori E, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis. 2009;64:320–6.
Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection. 2000;28:367–73.
Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138:1044–51.
Attman E, Aittoniemi J, Sinisalo M, Vuento R, Lyytikainen O, Karki T, et al. Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital. Leuk Lymphoma. 2015;56:3370–7.
Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21:337–43.
Klastersky J. Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness. Curr Opin Oncol. 1998;10:284–90.
Kaye KS, Marchaim D, Chen TY, Chopra T, Anderson DJ, Choi Y, et al. Predictors of nosocomial bloodstream infections in older adults. J Am Geriatr Soc. 2011;59:622–7.
Perez-Garcia A, Landecho MF, Beunza JJ, Conde-Estevez D, Horcajada JP, Grau S, et al. Enterococcal bloodstream infection. Design and validation of a mortality prediction rule. Int J Clin Pract. 2016;70:147–55.
Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Predictive scoring model of mortality in gram-negative bloodstream infection. Clin Microbiol Infect. 2013;19:948–54.
Tumbarello M, Trecarichi EM, Caira M, Candoni A, Pastore D, Cattaneo C, et al. Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality. PLoS One. 2012;7:e51612.
de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21:v252–v256.
Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013;98:1826–1835.
Hall KK, Lyman JA. Updated review of blood culture contamination. Clin Microbiol Rev. 2006;19:788–802.
Russell JA. Management of sepsis. N Engl J Med. 2006;355:1699–713.
Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann Hematol. 2013;92:533–41.
Liu J, Cheng Q, Yang Q, Li X, Shen X, Zhang L, et al. Prognosis-related factors in intensive care unit (ICU) patients with hematological malignancies: a retrospective cohort analysis in a Chinese population. Hematology. 2015;20:494–503.
Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999;11:7–12.
Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.
Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31:2810–8.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
Marin M, Gudiol C, Ardanuy C, Garcia-Vidal C, Jimenez L, Domingo-Domenech E, et al. Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. Clin Microbiol Infect. 2015;21:583–90.
Agrawal GN, Shevade SU. Comparison of Clinical and Laboratory Standards Institute 2008 and 2010 guidelines in interpreting susceptibility of enterobacteriaceae isolates. Indian J Pathol Microbiol. 2014;57:518–9.
Kanafani ZA, Dakdouki GK, El-Chammas KI, Eid S, Araj GF, Kanj SS. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade. Int J Infect Dis. 2007;11:450–3.
Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Salar A, Peris J, Granena A, et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999;18:539–44.
Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34:17–60.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.
Fletcher M, Hodgkiss H, Zhang S, Browning R, Hadden C, Hoffman T, et al. Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer. 2013;60:1299–306.
Zhai W, Zhang X, Wei J, Deng Q, Dong X, Zhang X, et al. A prospective observational study of antibiotic therapy in febrile neutropenia patients with hematological malignances from multiple centers in Northeast China. Int J Infect Dis. 2015;37:97–103.
Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica. 2010;95:1612–5.
Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58:299–307.
Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 2002;28:1718–23.
Hu FP, Zhu DM, Wang F, Jiang XF, Sun ZY, Chen ZJ, et al. CHINET 2013 surveillance of bacterial resistance in china. Chin J Infect Chemother 2014;15:365–74.
Kara O, Zarakolu P, Ascioglu S, Etgul S, Uz B, Buyukasik Y, et al. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis (Lond). 2015;47:686–93.
Acknowledgements
We thank all those who helped us in this study; in particular, the Department of Hematology and the Department of Clinical Laboratory for making this study possible. We thank Qing Yang for checking the English version of the manuscript and Di Zhang, Wei Cao, Qingxia Liu for providing patients to the study.
Funding
This work was supported by the Fundamental Research Funds for the Central Universities of Central South University No.2016zzts151 and No.2016zzts567, and the Education Reform Program for Central South University No. 2016JGB20.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest. All authors meet the ICMJE authorship criteria.
Ethical approval
This retrospective chart review study was evaluated by the Ethics Committee of the Central South University and deemed exempt from a formal review as no personally identifiable information would be collected.
Informed consent
The requirement for informed consent from patients was also waived.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tang, Y., Cheng, Q., Yang, Q. et al. Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections. Infection 46, 513–521 (2018). https://doi.org/10.1007/s15010-018-1151-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-018-1151-3